Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
385 studies found for:    (human papillomavirus OR hpv) AND (woman OR women OR female)
Show Display Options
Rank Status Study
21 Completed Evaluation of Immunogenicity Levels in Women With HPV Vaccine in Mexico
Conditions: Human Papillomavirus 16;   Human Papillomavirus 18;   Vaccines
Interventions: Biological: Bivalent Vaccines;   Biological: Tetravalent Vaccine
22 Completed Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix TM) Administered in Healthy Adolescents
Condition: Infections, Papillomavirus
Interventions: Biological: GSK Biologicals' HPV Vaccine GSK580299;   Biological: Engerix-B™
23 Completed The Human Papillomavirus (HPV) Transmission Pilot Study
Condition: Human Papillomavirus Infection
Intervention:
24 Completed Epidemiology of Papillomavirus Infection (HPV) on Infected Women by Human Immunodeficience Virus (HIV) in West Indies and French Guiana.
Conditions: 1- Women;   2- HIV Infection;   3- Followed in West Indies and French Guiana for His Infection;   4- Acceptance of the Use of Nadis® Medical Files
Intervention: Other: Biological Sample collection
25 Completed
Has Results
Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
Conditions: HIV Infections;   Sexually Transmitted Diseases
Intervention: Biological: Quadrivalent HPV vaccine
26 Recruiting Video to Promote HPV Vaccination
Conditions: Vaccine Acceptance;   Social Acceptance;   Acceptance Processes;   Health Behavior;   Human Papillomavirus
Intervention: Other: Educational Video with Male or Female Narrator
27 Active, not recruiting A Phase III Study of a 2-dose Regimen of a Multivalent Human Papillomavirus (HPV) Vaccine (V503), Administered to 9 to 14 Year-olds and Compared to Young Women, 16 to 26 Years Old (V503-010)
Condition: Human Papillomavirus Infection
Intervention: Biological: V503 (9-valent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) vaccine)
28 Enrolling by invitation Evaluate the Safety of Recombinant Human Papillomavirus Bivalent (Types 16 and 18) Vaccine (Yeast) in Healthy Females
Condition: Human Papillomavirus
Interventions: Biological: HPV 16/18 vaccine, 0,5ml;   Biological: Placebo control, 0.5ml;   Biological: HPV 16/18 vaccine, 1.0ml;   Biological: Placebo control, 1.0ml
29 Recruiting Vaginal Self-sampling and Human Papillomavirus Testing in Unscreened Women
Condition: Cancer Cervix
Interventions: Behavioral: Group 1 remove self sample kit at gp consulting room or perform pap smear;   Behavioral: Group 2 perform self sample at home or pap smear
30 Completed
Has Results
Human Papillomavirus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Biologicals Novel HPV Vaccine
Condition: Infections, Papillomavirus
Interventions: Biological: CervarixTM;   Biological: HPV investigational vaccine GSK568893A, different formulations
31 Active, not recruiting HPV Testing for Cervical Cancer Screening Study
Condition: Cervical Cancer Screening
Intervention: Procedure: Cervical cancer screening undertaken by HPV testing as a single primary screening test with cytology triage of women who are HPV positive
32 Completed
Has Results
Follow-up Study to Evaluate the Long-term Efficacy of the HPV Vaccine (580299) in Healthy Young Adult Women in Brazil
Conditions: HPV-16/18 Infections;   Cervical Neoplasia
Interventions: Procedure: Blood sampling;   Procedure: Collection of cervical specimen
33 Completed
Has Results
Immunogenicity and Safety of GSK Biologicals' HPV Vaccine 580299 in Healthy Japanese Females 10-15 Years of Age
Condition: Papillomavirus Vaccines
Intervention: Biological: Cervarix™ (HPV-16/18 L1 VLP AS04)
34 Completed
Has Results
Immune Response to the Human Papillomavirus Vaccine in Young Women With Inflammatory Bowel Disease
Conditions: Inflammatory Bowel Disease;   Uterine Cervical Dysplasia
Intervention: Biological: Human Papillomavirus Vaccine
35 Completed A Study to Examine the Human Papillomavirus Types Exposure in Women From Southern Africa and Brasil
Conditions: HIV;   HIV Infections
Intervention:
36 Completed
Has Results
Immunogenicity and Safety of GlaxoSmithKline Biologicals' Huma Papillomavirus (HPV) Vaccine 580299 in Healthy Females 15 - 25 Years of Age
Condition: HPV-16/18 Infections and Cervical Neoplasia
Intervention: Biological: Cervarix TM
37 Completed
Has Results
Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV Vaccine 580299 in Healthy Females 10 - 25 Years of Age.
Conditions: HPV-16/18 Infections;   Cervical Neoplasia
Interventions: Biological: CervarixTM;   Biological: Placebo vaccine (Al(OH)3)
38 Completed
Has Results
Dose-Ranging Study of Quadrivalent Human Papillomavirus (HPV) (Types 6,11,16,18) L1 Virus-Like Particle (VLP) Vaccine (V501-007)(COMPLETED)
Conditions: Papillomavirus Infections;   Genital Diseases, Female
Interventions: Biological: Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 20/40/40/20;   Biological: Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 40/40/40/40;   Biological: Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 80/80/40/80;   Biological: Placebo (mcg) (Aluminum Adjuvant)225;   Biological: Placebo (mcg) (Aluminum Adjuvant) 450
39 Recruiting Cervical Cancer Screening With Human Papillomavirus Testing
Conditions: CIN3;   CIN2;   Cervical Cancer
Intervention: Other: HPV screening
40 Completed Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003)
Conditions: Genital Warts;   Anal Cancer;   Anal Intraepithelial Neoplasia
Intervention: Biological: V503 Vaccine

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years